*ST Pharmaceutical (603963.SH): As of April 19, 2024, the number of shareholders of the company was 33,375

Gelonghui, April 30丨*ST Pharmaceutical (603963.SH) said on an interactive platform that as of April 19, 2024, the number of shareholders of the company was 33,375.

Gelonghui FinanceApr 30 05:48 ET

Dali Pharmaceutical (603963.SH) announced 2023 annual results with a net loss of 2003 million yuan

According to the Zhitong Finance App, Dali Pharmaceutical (603963.SH) disclosed its 2023 annual report. The company achieved revenue of 87.27 million yuan during the reporting period, a year-on-year decrease of 34.06%. The net loss attributable to shareholders of the listed company was RMB 200314 million, and the net loss attributable to shareholders of the listed company after deducting non-recurring profit and loss was RMB 25.22,900.

Zhitong FinanceApr 25 06:38 ET

Dali Pharmaceutical (603963.SH): Shenmai injections were not selected for procurement by the Hubei Provincial Federation of Proprietary Chinese Medicine

Zhitong Finance App News, Dali Pharmaceutical (603963.SH) issued a stock price change announcement stating that the company's Shenmai injections were not selected for procurement by the Hubei Provincial Federation of Proprietary Chinese Medicine, and that the sales volume of Shenmai injections in the original grade hospital market was basically lost. The company's Shengnaojing injections were selected by the Guangdong Six Provincial Proprietary Chinese Medicine Alliance, and sales of Xingnaojing injections will drop by a large percentage in the six allied provinces. The company has selected the National Proprietary Chinese Medicine Procurement Alliance for centralized volume procurement. Although sales are gradually picking up, gross profit has declined due to a sharp drop in sales prices.

Zhitong FinanceApr 10 05:23 ET

Optimistic Investors Push Dali Pharmaceuticalco.,Ltd (SHSE:603963) Shares Up 46% But Growth Is Lacking

Those holding Dali Pharmaceuticalco.,Ltd (SHSE:603963) shares would be relieved that the share price has rebounded 46% in the last thirty days, but it needs to keep going to repair the recent damage i

Simply Wall StMar 29 20:23 ET

7 Lianban Dali Pharmaceutical (603963.SH): There is no material information that should be disclosed but not disclosed

Gelonghui, March 20, 丨 Dali Pharmaceutical (603963.SH) announced that the company's stock trading closed for 7 consecutive trading days from March 12, 2024 to March 20, 2024, with a cumulative increase of 94.90%. The short-term increase was significantly higher than that of the same industry and the Shanghai Composite Index, with a cumulative turnover rate of 69%. According to the company's own investigation, up to now, the company, controlling shareholders, and actual controllers have no significant information that should have been disclosed but not disclosed.

Gelonghui FinanceMar 20 05:29 ET

7 Lianban Dali Pharmaceutical (603963.SH): The company's stock may be subject to a delisting risk warning by the Shanghai Stock Exchange

Dali Pharmaceutical (603963.SH) issued an announcement. The company's stock will be traded from March 12 to 202, 2024...

Zhitong FinanceMar 20 05:13 ET